Arcus Biosciences grants inducement awards to new employee
Arcus Biosciences granted options for 2,850 shares and RSUs for 1,450 shares to a new employee at an exercise price of $23.32 per share. The awards were approved by the Compensation Committee under the 2020 Inducement Plan, utilizing the NYSE inducement exception.
*this image is generated using AI for illustrative purposes only.
Arcus Biosciences granted equity awards to a new employee, consisting of options to purchase 2,850 shares and restricted stock units to acquire 1,450 shares of common stock. The options carry an exercise price of $23.32 per share, which was the closing price on June 8, 2026. These grants were made as an employment inducement under the company's 2020 Inducement Plan.
The Compensation Committee of Arcus Biosciences' Board of Directors approved the awards. The 2020 Inducement Plan was sanctioned by the Board in January 2020, utilizing the "inducement exception" outlined in NYSE Listed Company Manual Rule 303A.08. This regulatory provision allows companies to issue awards to new employees as an incentive for joining the organization.
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. The company collaborates with industry partners to expedite the development of its late-stage portfolio, targeting well-characterized biological pathways.
Award Details
| Award Type | Shares Granted | Exercise Price per Share |
|---|---|---|
| Options | 2,850 | $23.32 |
| Restricted Stock Units | 1,450 | N/A |
Founded in 2015, Arcus Biosciences has advanced multiple investigational medicines into registrational clinical trials. Key candidates include casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer.
What specific expertise or role does the new employee bring to support Arcus's late-stage clinical trials?
How will the recent equity awards impact Arcus's overall talent acquisition strategy in the competitive biopharmaceutical sector?
What are the expected timelines for the registrational trials of key candidates like casdatifan and quemliclustat?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
